Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Data (e.g. type of procedure, platelet count, etc.) will be collected retrospectively or
prospectively from patient visits occurring within approximately 7 calendar days prior to the
first dose of avatrombopag, on Procedure Day, on Discharge Day, and from any clinic visit
performed up to 30 days post-procedure. All treatment decisions and clinical assessments will
be at the discretion of the treating physician per routine medical care and are not mandated
by study design or protocol.

Inclusion Criteria:

- Patient has thrombocytopenia associated with chronic liver disease and is planned for
or underwent treatment with avatrombopag prior to a procedure

- Patient provides written informed consent

Minimum Data for Retrospective Enrollment

- Platelet count from approximately 7 days prior to starting avatrombopag

- Platelet count on Procedure Day